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Purpose: Subsequent to chemotherapy treatment, breast cancer patients often report a decline in cognitive
functioning that can adversely impact many aspects of their lives. Evidence has mounted in recent years indicating
that a portion of breast cancer survivors who have undergone chemotherapy display reduced performance on
objective measures of cognitive functioning relative to comparison groups. Neurophysiological support for
chemotherapy-related cognitive impairment has been accumulating due to an increase in neuroimaging studies in
this field; however, longitudinal studies are limited and have not examined the relationship between structural grey
matter alterations and neuropsychological performance. The aim of this study was to extend the cancer-cognition
literature by investigating the association between grey matter attenuation and objectively measured cognitive
functioning in chemotherapy-treated breast cancer patients.
Methods: Female breast cancer patients (n = 19) underwent magnetic resonance imaging after surgery but before
commencing chemotherapy, one month following treatment, and one year after treatment completion. Individually
matched controls (n = 19) underwent imaging at similar intervals. All participants underwent a comprehensive
neuropsychological battery comprising four cognitive domains at these same time points. Longitudinal grey matter
changes were investigated using voxel-based morphometry.
Results: One month following chemotherapy, patients had distributed grey matter volume reductions. One year
after treatment, a partial recovery was observed with alterations persisting predominantly in frontal and temporal
regions. This course was not observed in the healthy comparison group. Processing speed followed a similar
trajectory within the patient group, with poorest scores obtained one month following treatment and some
improvement evident one year post-treatment.
Conclusion: This study provides further credence to patient claims of altered cognitive functioning subsequent to
chemotherapy treatment.
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Patient reports of cognitive changes subsequent to chemo-
therapy exposure abound in the breast cancer population.
Self-perceived deterioration in mental functioning can
adversely impact work and family life for breast cancer
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in any medium, provided the original work is prelated cognitive impairment (CRCI) in breast cancer pa-
tients has mounted in the last several decades, as both
retrospective cross-sectional and prospective longitudinal
neuropsychological studies have found varying degrees of
cognitive under-performance in chemotherapy-exposed
breast cancer patients (for a review, see (O’Farrell et al.
2013)). Executive functioning, processing speed, and mem-
ory are domains frequently identified as vulnerable to
chemotherapy exposure in this population (Wefel and
Schagen 2012). Meta-analyses suggest that CRCI is subtle,an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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it is a transient phenomenon (Falleti et al. 2005; Stewart
et al. 2006). CRCI appears to have the greatest influence on
cognitive functioning immediately following treatment to
six months post treatment (Jim et al. 2012). However, some
studies have found mild impairment years beyond treat-
ment (Ahles et al. 2002; Koppelmans et al. 2012), while
others have found pre-chemotherapy impairment in the
breast cancer population (Ahles et al. 2007; Wefel et al.
2010), hinting at other contributing factors including the
disease itself and highlighting the need for prospective lon-
gitudinal study designs.
Neuroimaging studies of chemotherapy-exposed breast
cancer patients have started to elucidate the neural un-
derpinnings of CRCI (for reviews, see (McDonald and
Saykin 2013; Scherling and Smith 2013)). Research into
the neuroanatomical correlates of CRCI has employed
voxel-based morphometry (VBM) to explore grey matter
compromise in the breast cancer population (Inagaki
et al. 2007; Hakamata et al. 2007; Yoshikawa et al.
2005a; Yoshikawa et al. 2005b; McDonald et al. 2010;
McDonald et al. 2012a; Conroy et al. 2012; Scherling
et al. 2012a; Hosseini et al. 2012; De Ruiter et al. 2011a;
Koppelmans et al. 2011). VBM is a technique that en-
ables researchers to make voxel-by-voxel comparisons of
images of segmented brain matter volumes between
groups of participants in an automated and unbiased
manner (Ashburner and Friston 2000; Good et al. 2001).
The breast cancer literature suggests that the course of
grey matter loss is similar to the course of CRCI. An
early, retrospective VBM study found prefrontal and
temporal grey matter reductions in a chemotherapy-
exposed group four months after exposure; however,
these differences were not present when the same study
was conducted on a larger group a mean of 4.2 years
since chemotherapy exposure (Inagaki et al. 2007). Some
studies have found grey matter abnormalities in breast
cancer patients at approximately 9.5 years after treat-
ment (De Ruiter et al. 2011a) and 21 years after chemo-
therapy (Koppelmans et al. 2011), suggesting that a subset
of breast cancer patients exposed to chemotherapy are
vulnerable to long-term grey matter deficits after chemo-
therapy exposure. The first prospective VBM study to in-
vestigate chemotherapy-related brain matter changes in
breast cancer patients found no pre-chemotherapy struc-
tural differences between breast cancer patients and
healthy controls while conducting a whole-brain analysis
(McDonald et al. 2010). One month following treatment,
the chemotherapy-exposed group displayed distributed
grey matter attenuation that partially recovered one year
subsequent to treatment. That was the first study to dem-
onstrate a pattern of grey matter attenuation consistent
with the course of cognitive impairment reported in
neuropsychological studies, warranting a replication andextension study examining the link between neuropsycho-
logical functioning and grey matter disruption in chemo-
therapy treated breast cancer patients.
To date, only one VBM study has investigated the rela-
tionship between grey matter volume and the results of
a comprehensive neuropsychological assessment (Conroy
et al. 2012). In that retrospective study, grey matter density
in the right superior and middle frontal gyri was positively
correlated with post-chemotherapy interval. Furthermore,
overall neuropsychological performance was positively
related to mean grey matter density of these regions. In
light of those important findings, and given the cross-
sectional design of that study, there exists a need for
an increase in longitudinal studies examining grey
matter alterations and their relationship with neuro-
psychological functioning.
In the present study, we employed VBM to measure
longitudinal differences in whole-brain grey matter in
breast cancer patients exposed to chemotherapy and we
examined the relationship of these grey matter alterations
to performance on a comprehensive neuropsychological
battery. The present work extends a preliminary study con-
ducted by our group that compared pre-chemotherapy
volumetric differences between breast cancer patients and
healthy controls (Scherling et al. 2012a). Given that current
VBM studies suggest that grey matter reductions are most
pronounced soon after chemotherapy and partially resolve
over time (McDonald et al. 2010; Conroy et al. 2012), it was
hypothesized that breast cancer patients would have
broadly reduced grey matter volumes following chemother-
apy and that some recovery would be observed one year
after treatment. We further hypothesized that frontotem-
poral areas exhibiting grey matter loss would be related to
cognitive dysfunction, based on two lines of evidence. First,
participants of this study were a subset of participants from
a larger neuropsychological study (Collins et al. 2013) that
showed a dose-response decline of cognitive functioning.
Secondly, previous studies have demonstrated grey matter
loss in frontotemporal regions and functional studies
(Ferguson et al. 2007; McDonald et al. 2012b; De Ruiter
et al. 2011b; Kesler et al. 2011; Kesler et al. 2009; López
Zunini et al. 2013) have shown abnormal activations in
these areas during executive functioning and memory tasks.
Materials and method
Participants
Twenty-three early-stage breast cancer patients and 23
healthy controls matched on age, sex, and education
were recruited from the Ottawa Hospital Regional Cancer
Centre following patient surgery to remove the cancer, but
before patient chemotherapy commencement. Two patients
withdrew from the study after treatment. At one year
post-treatment, one patient withdrew and another had a
recurrence and was excluded from the study. Members
Table 1 Demographic and clinical characteristics
Patients (n = 19) Controls (n = 19) p-value
Age at baseline (years) 50.2 (8.6) 49.3 (9.0) 0.76
Education 0.66
High School 2 3
College 8 8
Undergraduate Degree 5 2
Graduate Degree 4 6









FEC-D (six cycles)1 12 –
FEC-D (five cycles) 1
CD (four cycles) 4 –
CDOX (four cycles)2 2 –
Type of surgery
Modified Radical MX 7 –
Simple MX 1 –
Segmental MX 3 –
Lumpectomy 8 –
Time between (days)
Surgery to T1 MRI 49.9 (15.2) –
T1 MRI to chemo 6.2 (4.9) –
End chemo to T2 MRI 32.0 (15.3) –
T1 MRI to T2 MRI 128.8 (23.0) 127.0 (25.0) 0.81
T2 MRI to T3 MRI 406.16 (70.3) 449.7 (106.9) 0.15
Mean (SD) or count values are shown. Units are arbitrary unless otherwise
specified. FEC-D: fluorouracil + epirubicin + cyclophosphamide + docetaxel; CD:
cyclophosphamide + docetaxel; CDOX: cyclophosphamide + doxorubicin; MX:
mastectomy. 1Two cases with epirubicin and one case with bevacizumab; 2one
case with paclitaxel.
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nomination or via print and web-based advertisements.
The final sample for this study consisted of 19 breast
cancer patients and 19 healthy controls. The present
sample is a subset of participants from a larger study in
which 60 breast cancer patients and their matched con-
trols underwent longitudinal neuropsychological assess-
ment (Collins et al. 2013) with a portion (38%) agreeing
to further participate in imaging studies. As part of a
larger imaging study, participants performed fMRI tasks
related to verbal memory retrieval, response inhibition,
and working memory following the structural scan
(López Zunini et al. 2013; Scherling et al. 2011; Scherling
et al. 2012b).
Clinical and demographic characteristics, including
chemotherapy regimens, are listed in Table 1. Inclusion
criteria for both groups were: 1) female; 2) no previous
history of cancer or chemotherapy; 3) between 18 and
65 years of age at diagnosis; 4) fluent in English; and, 5)
minimum of grade 8 education. Potential participants
were excluded due to the presence of any of the following:
1) metastasis of disease beyond axillary lymph nodes, 2)
neo-adjuvant chemotherapy treatment, 3) serious psychi-
atric illness, neurological illness, or substance abuse, 4)
MRI incompatibilities (e.g. metal implants, claustrophobia).
This study was approved by the Ottawa Hospital Research
Ethics Board and the University of Ottawa Research Ethics
Board.
Consent
Written informed consent was obtained from all partici-
pants for the publication of this study and its accom-
panying images.
Neuropsychological assessment
Prior to chemotherapy, following each patient’s chemo-
therapy cycle, and one year after treatment completion,
patients underwent a pencil-and-paper neuropsycho-
logical test battery as well as a computerized cognitive
test (CNS-Vital Signs (Gualtieri and Johnson 2006;
Gualtieri and Johnson 2008)). The traditional neuro-
psychological tests (Wechsler 1997; Army 1944; Fischer
et al. 2001; Rao et al. 1991; Brown 1958; Delis et al. 2001;
Brandt and Benedict 2001; Benedict 1997), listed in Table 2,
were selected to parallel the cognitive domains covered
by the computerized test battery and on the basis of
their previously-observed sensitivity to the effects of
cancer treatments (Stewart et al. 2008), their estab-
lished reliability and validity (Wechsler 1997; Delis
et al. 2001; Brandt and Benedict 2001; Benedict 1997;
Lezak et al. 2004; Strauss et al. 2006), and the recom-
mendations from the International Cognition and
Cancer Task Force (Wefel et al. 2011). To mitigate
practice effects, raw neuropsychological patient datawere converted to standardized scores based on the
means and standard deviations of the control group.
Four domain-specific cognitive summary scores were
computed on rational and empirical grounds: Process-
ing Speed, Working Memory, Verbal Memory, and
Visual Memory. Further elaboration of the assessments
and the methodology employed to create the cognitive
domains used in this study is provided elsewhere
(Collins et al. 2013). Neuropsychological data obtained
closest to, but not surpassing, MRI data acquisition
were used for analysis.
Table 2 Neuropsychological battery organized by cognitive domain
Processing speed Working memory Verbal memory Visual memory
Digit-Symbol Coding, WAIS-III
(Wechsler 1997)
Digit Span, WAIS-III (Wechsler 1997) Hopkins Verbal Learning Test-
Revised (HVLT-R) (Brandt and
Benedict 2001)
Brief Visuospatial Memory Test-





CNS-VS Verbal Memory Index
(Gualtieri and Johnson 2006;
Gualtieri and Johnson 2008)
CNS-VS Visual Memory Index
(Gualtieri and Johnson 2006;
Gualtieri and Johnson 2008)
Trail Making Test A (Trails A)
(Army 1944)
Paced Auditory Serial Addition Task
(PASAT) (Fischer et al. 2001; Rao
et al. 1991)
Trail Making Test B (Trails B)
(Army 1944)
Auditory Consonant Trigrams Test
(CCCs) (Brown 1958)
CNS-VS Processing Speed Index
(Gualtieri and Johnson 2006;
Gualtieri and Johnson 2008)
Controlled Oral Word Association
Test (COWA) (Delis et al. 2001)
CNS-VS Reaction Time Index
(Gualtieri and Johnson 2006;
Gualtieri and Johnson 2008)
CNS-VS Flexibility Index (Gualtieri
and Johnson 2006; Gualtieri and
Johnson 2008)
CNS-VS Working Memory Index
(Gualtieri and Johnson 2006;
Gualtieri and Johnson 2008)
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MRI data for the patient group were acquired at three
time points, with patient data acquired in similar intervals:
T1) after surgery but before chemotherapy, radiation, and/
or anti-estrogen treatment; T2) approximately one month
subsequent to chemotherapy regimen completion; and T3)
approximately one year following chemotherapy.
All images were acquired with a 1.5 Tesla Siemens Mag-
netom Symphony MR scanner. A gradient echo localizer
was acquired and used to prescribe a 3D FLASH (Fast Low
Angle SHot) spoiled gradient sequence with the following
parameters: TR = 629 ms, TE = 15 ms, field of view: 187 ×
250 mm, flip angle: 90 degrees, acquisition matrix: 256 ×
192, 5 mm thick axial slices, voxel size 1 × 1 × 5 mm.
The 3D data were analyzed using FSL-VBM (Douaud
et al. 2007), an ‘optimized’ VBM protocol (Good et al.
2001) implemented in FSL tools (Smith et al. 2004). The
brain extraction tool BET (Smith 2002), was used to re-
move skin and skull. Subsequently, the brain-extracted
images were tissue-segmented and the grey matter par-
tial volume images were registered to the MNI152
standard space using non-linear registration (Andersson
et al.). The registered images were averaged and flipped
along the x-axis to create a symmetric, study-specific
grey matter template in order to reduce the effect of
inter-subject variability during registration. The native
grey matter images were then linearily re-registered to
this template and modulated (i.e. divided by the Jabobian
of the warp field) to correct for local expansion or con-
traction due to the non-linear component of the spatial
transformation. Smoothing with an isotropic Gaussian
kernel with a sigma of 3 mm was applied to the modu-
lated grey matter images.Next, within-group voxel-wise threshold-free cluster
enhancement-based (Smith and Nichols 2008) GLM
analyses were conducted using permutation-based non-
parametric testing with 5,000 permutations on whole-
brain grey matter volumes. Statistical maps of within-
group comparisons thresholded at p < 0.01 uncorrected
for multiple comparisons were used to generate region
of interest (ROI) masks. Uncorrected values were used
as a means of selecting ROIs for further analysis. A com-
posite whole-brain mask covering all regions of signifi-
cant differences and 14 masks covering the intersection
of these regions and anatomical ROIs were defined with
the AAL atlas tool (Tzourio-Mazoyer et al. 2002) using
WFU PickAtlas (Maldjian et al. 2004; Maldjian et al.
2003) were created.
Region of interest analysis
Using R (The R Project for Statistical Computing, www.
r-project.org), ROI data were compared across time
points with Welch’s t-tests and p values were adjusted
for multiple comparisons using the Benjamini-Hochberg
procedure (Benjamini and Hochberg 1995).
Neuropsychological and demographic data
Differences across neuropsychological scores were inves-
tigated with repeated measures ANOVA and Tukey pair-
wise comparisons. The relationship between grey matter
volumes and neuropsychological performance within the
patient group was examined with HLM7 (Raudenbush
et al. 2011) using a two-level hierarchical linear model
(HLM) (Raudenbush and Bryk 2002) with time points
nested within patients. Distinct HLM analyses were con-
ducted in order to assess the correlation between each
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Demographic characteristics are listed in Table 1. The
patient group ranged in age from 35 to 64 years and the
controls ranged in age from 31 to 61 years. The interval
between scanning sessions did not differ between groups
(p > 0.05, Table 1). For patients, T1 neuropsychological
assessments were conducted on average 10.20 days (SD =
8.12) before chemotherapy, T2 neuropsychological assess-
ments were conducted on average 17.75 days (SD = 7.17)
after final chemotherapy exposure, and T3 neuropsycho-
logical assessments were completed on average 392.5 days
(SD = 46.77) following T2 assessments. After T2 and before
T3, 10 patients commenced hormonal therapy. Similarly,
during this interval 13 patients underwent radiotherapy.
Between T2 and T3, all patients that were either menstruat-
ing or perimenopausal at T1 became menopausal; however,
this status did not change for controls.
Within-group grey matter changes
Table 3 shows the grey matter volume differences be-
tween scans for patients in the composite whole-brain
mask and ROIs. At T2 relative to T1, patients showed a
reduction of grey matter volume in frontal, temporal,Table 3 Longitudinal changes in patient VBM values
Pre-chemo to 1-month post (n = 19) Pre-ch
Regions Mean Δ T value p value Mean
Composite Whole-Brain -909.08 ± 162.64 -11.70 <0.001 -387.7
Left Hemisphere
Medial Orbitofrontal Gyrus -5.85 ± 3.11 -3.94 0.003 -2.52 ±
Inferior Orbitofrontal Gyrus -9.62 ± 4.29 -4.69 <0.001 -3.62 ±
Inferior Frontal Operculum -26.21 ± 11.68 -4.70 <0.001 -15.70
Middle Temporal Gyrus -95.23 ± 40.65 -4.90 <0.001 -48.55
Insular Cortex -20.91 ± 8.48 -5.16 <0.001 -16.14
Superior Temporal Gyrus -79.35 ± 29.94 -5.55 <0.001 -40.30
Anterior Cingulate -15.49 ± 5.14 -6.30 <0.001 -8.87 ±
Calcarine Cortex -3.70 ± 1.80 -4.41 <0.001 -0.43 ±
Right Hemisphere
Middle Frontal Gyrus -8.30 ± 3.70 -4.70 <0.001 -4.97 ±
Gyrus Rectus -29.36 ± 12.97 -4.74 <0.001 -3.99 ±
Paracentral Lobule -34.50 ± 14.91 -4.84 <0.001 -18.34
Precuneus -6.89 ± 2.61 -5.53 <0.001 -5.61 ±
Hippocampus -11.41 ± 3.63 -6.58 <0.001 -7.89 ±
Anterior Cingulate -11.20 ± 4.88 -4.80 <0.001 -4.99 ±
Units are mm3; Mean Δ: mean difference ± 95% confidence interval.parietal, and occipital regions (Figure 1). There were no
areas of increased volume at T2 relative to T1. At one
year after chemotherapy relative to T1, significant grey
matter reductions were observed in bilateral frontal and
temporal regions and all other reductions observed from
T1 to T2 were no longer significant. Controls did not
show any decrease from T1 to T2; however, they did dis-
play an unexpected increase in grey matter volume in
the right amygdala from T1 to T2. At T3 relative to T1,
this increase was no longer significant; yet, there was a
significant increase in grey matter volume in the left lin-
gual gyrus.
Cognitive domain scores
Patient mean scores are presented in Table 4. An ana-
lysis of variance for processing speed revealed a signifi-
cant difference among the time points (F(2, 35) = 14.59,
p < 0.001). A post hoc Tukey test showed that patients
scored significantly better at baseline relative to T2 (p <
0.001) and T3 (p = 0.004). Although processing speed
scores improved from T2 to T3, this difference was only
marginally significant (p = 0.094). Scores on the three
other cognitive domains degraded over time; however,
the observed differences were not significant.
Cognitive functioning and relationship to grey matter
volumes
Listed in Table 5 are the correlations between ROI grey
matter volumes and the four cognitive domains. Processingemo to 1-year post (n = 19) 1-month post to 1-year post (n = 19)
Δ T value p value Mean Δ T value p value
8 ± 164.58 -4.95 <0.001 535.88 ± 186.53 6.04 <0.001
3.59 -1.474 0.158 3.63 ± 4.17 1.83 0.130
4.75 -1.61 0.125 6.40 ± 4.29 3.13 0.008
± 10.29 -3.20 0.007 12.38 ± 14.28 1.82 0.085
± 74.59 -1.37 0.188 47.47 ± 65.50 1.52 0.152
± 11.29 -3.00 0.011 4.82 ± 11.29 0.90 0.381
± 24.20 -3.50 0.004 42.86 ± 27.16 3.32 0.004
8.08 -2.31 0.033 5.83 ± 9.04 1.36 0.192
2.35 -0.39 0.703 3.11 ± -2.18 2.99 0.011
3.26 -3.20 0.007 3.92 ± 4.52 1.82 0.085
21.89 -0.38 0.706 24.03 ± 20.51 2.46 0.036
± 21.67 -1.78 0.092 17.40 ± -16.53 2.21 0.060
5.84 -2.02 0.089 0.80 ± 6.17 0.27 0.788
5.71 -2.91 0.014 3.01 ± 5.11 1.24 0.232
5.74 -1.82 0.100 5.42 ± 6.53 1.74 0.100
Figure 1 Images are presented in radiological view where right is the patient’s left side and left is the patient’s right side. Coordinates
presented in MNI space. a) middle frontal gyrus (36 28 22); b) precuneus (20 -58 25); c) gyrus rectus (6 48 -20); d) hippocampus (34 -14 -20) e) middle
temporal gyrus (-58 -4 -20); f) anterior cingulate (4 38 5); g) paracentral lobule (10 -36 75); h) medial orbitofrontal gyrus (-32 44 -5); i) inferior orbitofrontal
gyrus (-32 28 -5); j) superior temporal gyrus (-65 2 -5); k) insular cortex (-36 6 0); l) inferior frontal operculum (-54 10 0); m) anterior cingulate
(-10 38 10); n) calcarine cortex (-12 -86 5).
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composite (r= 0.61, p <0.001) and frontal, temporal, and
occipital areas. Working memory showed a positive rela-
tionship with the left medial orbitofrontal gyrus (r = 0.51,
p = 0.007) and the right middle frontal gyrus (r = 0.42, p <
0.05). Visual memory was positively related to grey matter
volume in the left inferior frontal operculum (r = 0.71,
p = 0.009) and the right middle frontal gyrus (r = 0.71,
p < 0.009). There was no relationship between grey
matter in the ROIs and composite whole-brain with
verbal memory.
Discussion
VBM analyses showed diffuse reductions in brain re-
gions of breast cancer patients one month after chemo-
therapy. This attenuation recovered in nearly half of the
regions one year post-chemotherapy. These results pro-
vide both evidence of a neural basis for CRCI and opti-
mism for the recovery from the injurious effects that
chemotherapy appears to have on the brain.Table 4 Patient within-group cognitive domain scores ANOVA
Time1 Time 2 Time 3
n = 19 n = 19 n = 19
Domain M SD M SD M S
Processing speed -0.05 1.03 -0.54 1.29 -0.43 1
Working memory -0.26 0.71 -0.36 0.70 -0.35 0
Verbal memory -0.18 1.14 -0.20 1.25 -0.64 1
Visual memory -0.08 0.93 -0.28 0.97 -0.39 1
Scores represent average z-scores on tests comprising each domain, referenced toOur primary hypothesis that grey matter alterations
would be more pronounced and distributed shortly after
chemotherapy and then partially resolve one year post-
chemotherapy was supported. Diffuse grey matter alter-
ations in the patient group approximately one month
after chemotherapy exposure is congruent with existing
VBM studies that have shown distributed grey matter
disruption in the breast cancer population shortly after
chemotherapy treatment (Inagaki et al. 2007; McDonald
et al. 2010; McDonald et al. 2012a). Additionally, our results
support the converging evidence from both structural
(Inagaki et al. 2007; McDonald et al. 2010; McDonald et al.
2012a) and functional studies (McDonald et al. 2012b; De
Ruiter et al. 2011b; Kesler et al. 2011; Kesler et al. 2009;
López Zunini et al. 2013; Silverman et al. 2007) that the
frontal lobes appear particularly sensitive to chemotherapy.
These findings are important in light of common reports of
acute executive function and working memory difficulties
in patients subsequent to chemotherapy (Wefel and Scha-
gen 2012) because these cognitive functions are subservedANOVA Tukey’s HSD
df = 2, 35 T1 to T2 T1 to T3 T2 to T3
D F-ratio p value p value p value p value
.19 14.59 <0.001 <0.001 0.004 0.094
.72 0.80 0.457 0.421 0.887 0.726
.44 2.40 0.105 0.993 0.121 0.154
.11 1.39 0.262 0.416 0.259 0.942
the control group mean and standard deviation at the same time point.
Table 5 Patient whole brain and ROI grey matter volume correlations with cognitive domains
Region Processing speed Working memory Verbal memory Visual memory
r t(18) p value r t(18) p value r t(18) p value r t(18) p value
Composite Whole-Brain 0.61 4.75 <0.001 0.01 0.09 0.933 0.05 0.16 0.877 0.18 0.85 .407
Left Hemisphere
Medial Orbitofrontal Gyrus 0.36 4.27 <0.001 0.51 3.05 0.007 -0.35 -1.20 0.244 0.19 0.88 0.393
Inferior Orbitofrontal Gyrus 0.36 3.91 0.001 0.12 0.75 0.461 -0.63 -1.81 0.088 -0.18 -0.75 0.461
Inferior Frontal Operculum 0.54 3.15 0.006 0.42 2.11 0.049 0.48 1.25 0.229 0.71 2.91 0.009
Middle Temporal Gyrus 0.21 1.29 0.213 -0.02 -0.15 0.883 0.24 0.76 0.457 0.14 0.63 0.540
Insular Cortex 0.44 4.21 <0.001 -0.07 -0.43 0.672 -0.10 -0.27 0.789 0.05 0.21 0.837
Superior Temporal Gyrus 0.56 4.56 <0.001 0.17 0.01 0.948 0.09 0.29 0.775 0.05 0.22 0.829
Anterior Cingulate 0.35 2.25 0.037 0.12 0.91 0.376 0.04 0.11 0.917 0.31 1.39 0.180
Calcarine Cortex 0.26 2.55 0.020 -0.01 -0.09 0.929 0.15 0.48 0.640 0.13 -0.56 0.582
Right Hemisphere
Middle Frontal Gyrus 0.54 3.15 0.006 0.42 2.11 0.049 0.48 1.25 0.229 0.72 2.91 0.009
Gyrus Rectus 0.14 0.94 0.359 0.09 0.56 0.582 0.15 1.25 0.229 0.32 1.50 0.150
Paracentral Lobule 0.58 3.86 0.001 0.14 -0.85 0.408 0.04 0.15 0.886 -0.02 -0.09 0.932
Precuneus 0.19 1.25 0.227 -0.04 -0.38 0.709 0.13 0.39 0.698 0.16 0.59 0.564
Hippocampus 0.26 1.95 0.066 0.10 0.88 0.393 -0.12 -0.40 0.696 -0.08 -0.36 0.721
Anterior Cingulate 0.01 0.09 0.933 0.07 0.56 0.585 -0.15 -0.46 0.653 0.13 0.57 0.577
n = 19.
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Our findings of both attenuated grey matter volume
in the frontal lobes and the positive relationship be-
tween GM reduction in these regions with poorer
performance on executive function, working memory,
and visual memory strengthen the neuroanatomical
evidence of CRCI.
In contrast to one month post-chemotherapy, fewer re-
gions displayed reduced GM at one year post-treatment
relative to baseline. Regions displaying persistent grey mat-
ter loss remained bilaterally distributed in frontotemporal
regions. Enduring frontal grey matter suppression was
found in the left anterior cingulate gyrus, left inferior
frontal operculum, and right middle frontal gyrus, congru-
ent with a previous report of chronic frontal insult in
chemotherapy-treated breast cancer patients (McDonald
et al. 2010). The region of the left superior temporal gyrus
and left insula that had pronounced reduction at T2 relative
to T1 (see Figure 1) did not fully resolve. The superior
temporal gyrus and insula share efferent and afferent
connections (Flynn 1999) and this may help explain
the concomitant insults to these regions observed in
the present study. Interestingly, the right hippocampus
displayed reduced grey matter, concordant with previous
studies that have demonstrated prolonged hippocampal
compromise (McDonald et al. 2010; Kesler et al. 2013;
Bergouignan et al. 2011), but in contrast to a study by
Yoshikawa et al. (Yoshikawa et al. 2005a) that failed to find
hippocampal insult.The diffuse nature of grey matter modulation observed
in this and similar studies, along with some of the re-
gional volume loss discordance across extant grey matter
studies of chemotherapy in breast cancer, may be attrib-
utable to the inclusion of heterogeneous chemotherapy
regimens. Although nearly all cytostatic agents have
been associated with neurobiological effects, the mecha-
nisms and outcomes vary across treatments (for a re-
view, see (Seigers et al. 2013)). Some chemotherapeutic
agents, such as methotrexate, 5-fluorouracil, and cyclo-
phosphamide, appear to have direct cytotoxic effects via
their ability to penetrate the blood-brain-barrier (BBB)
(Dietrich 2010); however, other agents appear to have in-
direct effects due to their inability to cross the BBB. A
recent study by Kesler et al. (Kesler et al. 2013) suggests
that elevated pro-inflammatory cytokine expression, as
seen in BBB impermeable agents like doxorubicin, may
have direct and indirect injurious effects on brain struc-
tures. Our present study included both BBB permeable
and impermeable chemotherapeutic agents (see Table 1).
It will be important for future studies to tease apart the
differential effects of various chemotherapy treatments
on the brain.
Our secondary hypothesis that grey matter attenuation
would be related to cognitive functioning was supported.
Although processing speed was positively related to dis-
tributed grey matter volumes, the association was ob-
served predominantly in frontotemporal regions. This
included the left insula and a portion of prefrontal areas
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(Flynn 1999), specifically, the left medial and inferior re-
gions of the orbitofrontal cortex (OFC) and the left in-
ferior frontal operculum. The insula is critical for neural
communication between the prefrontal cortex and more
posterior regions (Augustine 1996) and disruption to the
insula and associated regions may underlie some of the
cognitive difficulties expressed by chemotherapy-exposed
breast cancer patients.
Interestingly, processing speed and working memory
were positively correlated with grey matter volume in
the medial orbitofrontal gyrus. This is a notable finding
given the clinical implications. Previous studies have
associated the OFC with a range of cognitive processes
including decision making (Plassmann et al. 2010), emotion
(Rolls & Grabenhorst 2008), and response inhibition (Horn
et al. 2003). Grey matter loss in this region of the OFC was
significant for patients between pre-chemotherapy exposure
and one month post-treatment, consistent with the pattern
of decreased cognitive performance during the same inter-
val. Our findings underscore the extensive impact that
exposure to chemotherapy may have on breast cancer pa-
tients. In light of our results, work showing that the OFC is
involved in processes beyond the cognitive domains se-
lected in our study points to a potential for chemotherapy
exposure to adversely impact the lives of breast cancer
patients more widely than suggested by our results alone.
The strengths of this study include its longitudinal de-
sign and the administration of a comprehensive battery
of objective neuropsychological measures that covered a
broad range of cognitive processes. We acknowledge
that there are limitations to our study that necessitate a
degree of caution when interpreting our findings. Pri-
marily, we did not include a chemotherapy-naïve com-
parison group and, consequently, we could not control
for the potential influence of cancer-related factors.
Existing VBM studies that have included both a healthy
control group and a chemotherapy-naïve breast cancer
control group have found no within-group grey matter
differences in these control groups in contrast to the de-
cline observed in chemotherapy-exposed breast cancer
patients (McDonald et al. 2010; McDonald et al. 2012a),
suggesting that grey matter alterations may stem from
chemotherapy exposure.
The number of treatment cycles and types of surgery
varied across breast cancer patients (see Table 1). Given
our limited sample size, we could not control for the
influence of these potentially confounding factors. Cur-
rently, one cross-sectional study has examined the ef-
fects of a heterogeneous chemotherapy regimen on grey
matter volumes in a large sample (Koppelmans et al.
2011); it will be important for future longitudinal inves-
tigations to employ a similar approach. Treatment-
induced menopausal symptoms co-occur with cognitiveimpairment following chemotherapy in breast cancer
patients (Fan et al. 2005). Although our patients and
controls were closely matched at baseline, at T3 relative to
T2 all patients were menopausal while controls remained
unchanged. As a result, we were unable to control for the
effects of menopausal status. From time T2 to T3, some pa-
tients received radiotherapy or commenced hormonal ther-
apy. Reports in the literature suggest that these treatments
may perturb cognition (Quesnel et al. 2009; Bender
et al. 2001). However, despite their administration, an
overall improvement in GM volumes was observed
from T2 to T3, suggesting that these therapies may
have had a negligible effect.
In summary, the present study demonstrated grey matter
volume loss in diffuse brain regions in breast cancer pa-
tients one month following chemotherapy treatment. One
year following treatment, grey matter was partially recov-
ered. Grey matter volumes were related to cognitive per-
formance in the domains of processing speed, working
memory, and visual memory. Cognitive dysfunction was
found to follow a similar course to grey matter changes,
particularly in the domain of processing speed. This study
strengthens the evidence for the relationship between brain
alterations and objectively measured cognitive difficulties
in breast cancer patients exposed to chemotherapy. In
addition to the burden of being diagnosed with a life-
threatening disease, breast cancer patients must contend
with potential adverse side effects of treatment. Cognitive
and neurophysiological alterations touch many areas of sur-
vivors’ lives, warranting future research to further elucidate
the mechanisms of CRCI and to improve breast cancer pa-
tients’ quality of life.Ethical standards
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